Coloplast A/S Sponsored ADR (OTCMKTS:CLPBY – Get Free Report) was the recipient of a significant increase in short interest in July. As of July 31st, there was short interest totaling 224,453 shares, an increase of 90.8% from the July 15th total of 117,659 shares. Approximately 0.0% of the company’s stock are sold short. Based on an average trading volume of 613,487 shares, the days-to-cover ratio is currently 0.4 days.
Analysts Set New Price Targets
Separately, Kepler Capital Markets raised shares of Coloplast A/S to a “strong-buy” rating in a research report on Wednesday, May 20th. One research analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold”.
Get Our Latest Stock Analysis on CLPBY
Coloplast A/S Stock Down 0.4%
Coloplast A/S Company Profile
Coloplast A/S is a global developer and manufacturer of medical devices and services focused on intimate healthcare. The company specializes in solutions designed to assist individuals with chronic medical conditions, aiming to improve quality of life through innovative products. Coloplast’s offerings span ostomy care, continence care, wound and skin care, and interventional urology, targeting patients who require long-term support and specialized treatments.
In its ostomy business, Coloplast provides pouches, skin barriers and accessories for patients who have had surgical procedures to divert bodily waste.
Further Reading
- Five stocks we like better than Coloplast A/S
- The Metals Company’s Big Bet Now Comes Down to a License
- OneSpaWorld Keeps Turning Cruise Demand Into Record Earnings
- Meta and Tesla Are Rebounding From Oversold Levels—Now What?
- AMG’s Alternatives Boom Powers Record Growth
Receive News & Ratings for Coloplast A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coloplast A/S and related companies with MarketBeat.com's FREE daily email newsletter.
